#LAURUSLABS Laurus lab hit second target.
FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
LAURUSLABS
1,009
+75.75 (8.12%)
Updated 03:29 03/08 IST
LAURUSLABS Buy or Sell - FrontPage Forums
0 Users have submitted 0 trade ideas of Rs. 0 for LAURUSLABS
Disclaimer0% Bullish
0% Bearish
LAURUSLABS Buy or Sell - Brokerage Reports
No. of reports in last year
1
No. of analysts
1
Average Consensus Forecast
471
Consensus Potential
-98.14%
LAURUSLABS Ratings
Long term LAURUSLABS rating by FrontPage users
- ★★
- ★★
- ★★
- ★★
- ★★
5/5 (3 Ratings)
Find answers to all your questions on live LAURUSLABS message board: Is LAURUSLABS buy or sell? Should I buy LAURUSLABS shares? Why are LAURUSLABS shares falling? Should I invest in LAURUSLABS stock?
- Home
- LAURUSLABS Forum
LAURUSLABS Share Price Discussion
G
Reputation: 4,923 • Today 1:41 AM
Great Eagle Analysis in LAURUSLABS#LAURUSLABS MEDIUM TERM BUY MODE TGT 762/1028 ...
Like
Reply
A
Reputation: 2,612 • Today 6:34 AM
ASHISH SHAH in LAURUSLABSIntraday Short View Laurus Labs looks good 1040...
Like
Reply
T
Reputation: 239 • Today 3:03 AM
Like
Reply (2)
Latest replies
#LAURUSLABS UP 9% 🚀🚀🚀
#TATAMOTORS @ 112 FROM INTRADAY DIP OF 109.
N
Reputation: 4,625 • Yesterday 3:26 AM
Ashok Leyland may prove to be the dark horse in auto space: Abhimanyu Sofat
Considering the stock is quite diversified, from commercial vehicles to defence, you could see a lot of traction coming over next two-three years.
Considering the stock is quite diversified, from commercial vehicles to defence, you could see a lot of traction coming over next two-three years.
The Economic Times
Like
Reply
N
Reputation: 4,625 • Aug 1 3:16 AM
Pharma stocks gain as investors rush to buy defensives
In the last five trading sessions, Nifty Pharma index has rallied 9% as against 1% drop in the Nifty.
In the last five trading sessions, Nifty Pharma index has rallied 9% as against 1% drop in the Nifty.
The Economic Times
Like
Reply
T
Reputation: 239 • Jul 31 2:39 AM
NIFTY SETTLING AT 35 POINTS GAP UP IN PRE OPEN POST A BIG GAP UP... SOME SELLING PRESSURE ON TOP...
STOCKS TO TRADE
Like
Reply
N
Reputation: 4,625 • Jul 30 1:28 AM
Aarti Drugs’ API business gains as pharma firms diversify raw material sourcing from China
Company’s stock among those that gained substantially during COVID-19 days. Drug maker planning contract manufacturing of specialty products. Other Indian pharma companies also benefit as buyers, both domestic and global, scout for non-Chinese suppliers of raw materials.
Company’s stock among those that gained substantially during COVID-19 days. Drug maker planning contract manufacturing of specialty products. Other Indian pharma companies also benefit as buyers, both domestic and global, scout for non-Chinese suppliers of raw materials.
Moneycontrol
Like
Reply
N
Reputation: 4,625 • Jul 30 11:33 AM
Laurus Labs' net up 11 times to Rs 172 crore in Q1
Revenues from operations were up 77 percent during the quarter under discussion to Rs 974 crore, a press release said.
Revenues from operations were up 77 percent during the quarter under discussion to Rs 974 crore, a press release said.
Moneycontrol
Like
Reply
N
Reputation: 4,625 • Jul 30 10:36 AM
Laurus Labs Q1 results: Net profit up 11 times to Rs 172 crore
Revenues from operations were up 77 per cent during the quarter under discussion to Rs 974 crore, a press release said.
Revenues from operations were up 77 per cent during the quarter under discussion to Rs 974 crore, a press release said.
The Economic Times
Like
Reply
T
Reputation: 13,713 • Jul 30 6:51 AM
FROM SOURCES : LAURUS LAB LIKELY TO REPORT 148 CR PROFIT VS EXPECTATION OF 92 CR TODAY. 5:1 STOCK SPLIT ALSO POSSIBLE.
Like
Reply
G
Reputation: 4,923 • Jul 29 2:16 AM
Great Eagle Analysis in LAURUSLABS#LAURUSLABS MEDIUM TERM BUY MODE TGT 762/1028 ...
Laurus lab Hit my first tgt. 21.92% return from my suggested level. Book 70% and hold rest for final target.
Like
Reply
N
Reputation: 4,625 • Jul 29 4:46 AM
FPIs, MFs both turn gung-ho on these 12 stocks; they’re worth a look
Domestic mutual funds and foreign portfolio investors (FPIs) both turned bullish on at least a dozen common stocks in June quarter.
Domestic mutual funds and foreign portfolio investors (FPIs) both turned bullish on at least a dozen common stocks in June quarter.
The Economic Times
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
- keyboard_arrow_down
LAURUSLABS Share Price - Technicals
- NewsBotAug 1 3:16 AMPharma stocks gain as investors rush to buy defensivesThe Economic TimesNewsBotJul 30 11:33 AMLaurus Labs' net up 11 times to Rs 172 crore in Q1MoneycontrolNewsBotJul 30 10:36 AMLaurus Labs Q1 results: Net profit up 11 times to Rs 172 croreThe Economic TimesNewsBotJul 29 4:46 AMFPIs, MFs both turn gung-ho on these 12 stocks; they’re worth a lookThe Economic TimesNewsBotJul 17 4:26 AM
Share market update: 28 stocks hit 52-week highs on NSE - The Economic TimesThe Economic TimesNewsBotJul 14 4:46 AM
Share market update: 35 stocks hit 52-week highs on NSE - The Economic TimesThe Economic TimesNewsBotJul 13 12:38 PM
Hot Stocks | Some profit-booking likely; Sunteck Realty, Laurus Labs two buy calls for the short-termMoneycontrolNewsBotJul 2 4:23 AM
Lovable Lingeri Standalone March 2020 Net Sales at Rs 10.58 crore, down 61.92% Y-o-YMoneycontrolNewsBotJun 29 3:38 AM
Bluewater Investment offloads Rs 632 crore stake in Laurus Labs, Titan Europe sells shares worth Rs 146.74 crore in Wheels IndiaMoneycontrolNewsBotJun 29 2:36 AM
NSE-BSE bulk deals: Blue Water Investment sells Laurus LabsThe Economic Times
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.